Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

Core Points - Cytokinetics (NASDAQ: CYTK) received a three-month extension on its Prescription Drug User Fee Act (PDUFA) date, now set for December 26, 2025, for FDA review [2] Group 1 - The FDA's extension allows more time for the review of Cytokinetics' regulatory application [2] - The article highlights the importance of the PDUFA date in the drug approval process [2]